Myelodysplastic Syndrome (MDS)

Intermediate and/or High Risk

Newly diagnosed

- IRB# 16867 - Abbvie 531 phase 1b venetoclax + azacitidine in treatment naïve subjects
- IRB# 16984 - Abbvie 532 venetoclax by itself or in combination with azacitidine in relapsed/refractory subjects

Relapsed/ refractory

- IRB# 16964 - FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
- IRB# 17379 - Novartis Phase 1B PDR001 and/or MBG453 with decitabine
- IRB# 19290 - Ph 1b Dose-escalation of PLX2853

Lower Risk

- IRB# 19978 - Study coming soon

Cross Disease Trial

- Cross Disease Trial - IRB# 19992 - EAY131 (MATCH)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

1/5/2020

http://www.ohsu.edu/research/nda/so/knight.php